Back to discover

Protein / target

DNA-directed RNA polymerase II subunit RPB1

Encoded byPOLR2AP24928Homo sapiensSwiss-Prot
2
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

DNA-directed RNA polymerase

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene POLR2A · Genetic evidence · score 0.79

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates.

View complete UniProt function annotation

Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092)

Subcellular location

NucleusCytoplasmChromosome
Domains and Gene Ontology detail (24)

Gene Ontology

  • Cchromosome
  • Ccytoplasm
  • Cnucleoplasm
  • Cnucleus
  • CRNA polymerase II, core complex
  • FDNA binding
  • FDNA-directed RNA polymerase activity
  • Fhydrolase activity
  • Fkinase binding
  • Fmagnesium ion binding
  • Fmicrofibril binding
  • Fpromoter-specific chromatin binding

1970 aa · 217 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase w…
  • ·RNA polymerase II, core complex
  • ·DNA-templated transcription termination
  • ·mRNA transcription by RNA polymerase II

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

TAS-106
Narrow target profileInhibitor

DNA-directed RNA polymerase II subunit RPB1 inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene POLR2A

Gene-level evidence surfaced through the gene POLR2Athat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn
0.79Well supported

Genetic evidence dominant · Open Targets 0.48

Autistic Disorder
0.49Limited support

Genetic literature evidence dominant · Open Targets 0.37

HIV Infections
0.40Preliminary

Pathway evidence dominant · Open Targets 0.60 · no direct causal or clinical evidence

Influenza, Human
0.26Preliminary

Pathway evidence dominant · Open Targets 0.37 · no direct causal or clinical evidence

Dengue
0.24Preliminary

Pathway evidence dominant · Open Targets 0.37 · no direct causal or clinical evidence

View evidence synthesis (5)
Genetic Diseases, InbornWell supported
0.79
agreement 0.650.93
Genetic100%Literature0%

Open Targets aggregate 0.48 · 2 independent evidence families

Autistic DisorderLimited support
0.49
agreement 0.330.64
Genetic literature100%

Open Targets aggregate 0.37 · 1 independent evidence family

HIV InfectionsPreliminary
0.40
agreement 0.170.62
Pathway100%

Open Targets aggregate 0.60 · 1 independent evidence family · no direct causal or clinical evidence

Influenza, HumanPreliminary
0.26
agreement 0.080.43
Pathway93%Literature7%

Open Targets aggregate 0.37 · 2 independent evidence families · no direct causal or clinical evidence

DenguePreliminary
0.24
agreement 0.010.47
Pathway100%

Open Targets aggregate 0.37 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
HIV Infections0.60
Genetic Diseases, Inborn0.48
Influenza, Human0.37
Autistic Disorder0.37
Dengue0.37

Safety-related annotations

thrombocytopeniaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

2

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

ClinicalTrials.gov via the drug-target graph.